Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting
Authors
Keywords
Melanoma, Vaccine, Immunotherapy, Adjuvant, GM-CSF
Journal
Journal of Translational Medicine
Volume 13, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-07-04
DOI
10.1186/s12967-015-0572-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine
- (2014) Yinin Hu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma
- (2014) F. Stephen Hodi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF-Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer
- (2014) G. Chen et al. Cancer Immunology Research
- Structure-Based Design of Altered MHC Class II-Restricted Peptide Ligands with Heterogeneous Immunogenicity
- (2013) S. Chen et al. JOURNAL OF IMMUNOLOGY
- Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
- (2012) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Alfons JM van den Eertwegh et al. LANCET ONCOLOGY
- Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
- (2012) Steffen Walter et al. NATURE MEDICINE
- Cancer Immunotherapy Comes of Age
- (2011) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
- (2011) Paul F. Robbins et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
- (2009) M. A. Cheever et al. CLINICAL CANCER RESEARCH
- Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation
- (2009) Leisha A. Emens et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy
- (2009) F. R. Depontieu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Allogeneic Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation
- (2008) D. Laheru et al. CLINICAL CANCER RESEARCH
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
- (2008) F. S. Hodi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More